ATRCAtriCure, Inc.

Healthcare

$55.80+53% 1Y

$55.80

$25.8652 weeks$60.73

Price

+53%1Y

End-of-day closes, not the intraday tick.

More going right than wrong

Quality strong, nothing alarming, price roughly fair, growth steady, the market undecided.

RyuScore 21 of 100: see how it is built

What they do

We are a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib or AF), left atrial appendage (LAA) management and post-operative pain management. Afib is an irregular heartbeat, or arrhythmia, which affects over 59 million people worldwide and is a growing epidemic. It is the most common cardiac arrhythmia encountered in clinical practice and results in high utilization of healthcare services and significant cost burden.

In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR

P/E265.7

Market value$1.42B

1 year+53%

5 years-26%

Charts

As reported to the SEC, without any scoring.

AtriCure, Inc. (ATRC) reported revenue of $154M in Q2 2026 (quarter ended Jun 30, 2026), up 13% from the same quarter a year earlier. That came with a gross margin of 77% and net income of $9.0M (5.8% of revenue). For the full year FY2025, revenue was $535M (+15% year on year) and net income −$11M. Its largest region in Q2 2026 was United States at $41M, 51% of the disclosed total, well ahead of Europe at 21%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

Jul 23, 2026AtriCure Reports Second Quarter 2026 Financial Results.Earnings release · press release
May 19, 2026At the AtriCure, Inc. (the “Company”) 2026 Annual Meeting of Stockholders held on May 18, 2026 (“Annual Meeting”), the stockholders of the Company approved an amendment to the AtriCure, Inc. 2023 Stock Incentive Plan (the “Amended 2023 Plan”)Director or officer change · Form 8-K
May 6, 2026AtriCure Reports First Quarter 2026 Financial Results.Earnings release · press release